Evidence Level
UC-II has a compelling evidence base centered on its unique oral tolerance mechanism. The Lugo et al. (2016) head-to-head trial was pivotal, showing UC-II 40mg daily outperformed the gold-standard combination of glucosamine 1,500mg + chondroitin 1,200mg for all WOMAC subscales over 180 days. Crowley et al. (2009) established efficacy vs. placebo in knee OA. The mechanism is distinct from other joint supplements: UC-II does not provide structural building blocks but rather trains the immune system to stop inflammatory attacks on type II collagen in cartilage. This requires the collagen to remain undenatured (native structure intact) and to be taken on an empty stomach to preserve its structure through the GI tract to Peyer patches.